查詢結果分析
來源資料
相關文獻
- 血液惡性疾病之體外化學藥物敏感試驗
- 血液惡性疾病之體外化學葯物敏感試驗
- 血液惡性疾病之體外化學葯物敏感試驗
- The Effect of Coagulation Protection with Combination of Epsilon Aminocaproic Acid and Plasma Saver in Open-Heart Surgery
- 血液幹細胞在臨床應用上的新展望
- Effective Relief of Obstructive Jaundice in a Patient with Nonresectable Icteric-type Hepatocellular Carcinoma by External Beam Radiation Therapy: Case Report
- 非生物性體外血液淨化在肝衰竭病人的治療上之角色
- 非生物性體外血液淨化在肝衰竭病人的治療上之角色
- Blood Viscosity and Cardiopulmonary Bypass --Emphassizing the Feasibility of Nonhemic Priming
- Influence of Cardiopulmonary Bypass on Viscosity of Blood in Open Heart Surgery
頁籤選單縮合
題名 | 血液惡性疾病之體外化學藥物敏感試驗 |
---|---|
作者姓名(中文) | 黃偉修; | 書刊名 | 醫學研究 |
卷期 | 11:3 1990.11[民79.11] |
頁次 | 頁185-192 |
分類號 | 415.656 |
關鍵詞 | 血液; 惡性疾病; 體外; 化學藥物; |
語文 | 中文(Chinese) |
中文摘要 | 本將各類血液性惡性疾病之惡生細胞,用短時間體外液體培養基中培養(In vitro short term liquid medium culture)方法,並以染料排除法(Dye exclusion assay, DEA)計算化學藥物之敏感度(Chemosensitivity),及不同濃度之藥物作用下,惡性細胞素殺作用之變化。本實驗共有18位各類血液惡性疾病,其中兩例死於敗血症;而在可評估的16例中則包括急性白血病(Acute leukemia)13例,慢髓若球性白血病合併急性芽細胞危象(CML with acute blastic crisis)例,惡性淋巴瘤合併骨髓侵犯(malignant lymphoma with bone marrow involvement)1例及多發性骨髓瘤(multiple myeloma)1例,而體外測試之化學藥物包括cytostine arabinoside(cytosar)、Adriamycin、Equirubicin、Dauomycin及Vincristine,結果發現在16病患中,體外測得對藥物敏感而臨床治療能得到完全緩解(Complete Remission)者10例中有8例,預測正確率為百分之八十。另體外測得對藥物具抗藥性(Resistance)者有6例,而臨床治療則全部都、法得到完全緩解,預測之正確率為百分之百。 本實驗發現以短時間體外液體培養方法並利用染料排除法測出之藥物敏感度之結果與臨床之治療效果十分吻合,且本實驗方便、快速,對臨床上藥物治療之選擇實用性高,並可進一步做臨床療效(Effectiveness)及抗藥性之評估。 |
英文摘要 | To determine if an in vitro assay could help in predicting clinical response, we studied 18 patients with hematologic malignancy. Tumor cells obtained by marrow aspiration were tested for chemosensitivity using a short term liquid medium culture and dye exclusion assay. Results were compared to subsequence response to treatment. Chemotherapeutic drugs were chosen without knowing the assay results. Two patients were excluded because of early death. The 16 patients studied included acute myelocgenous leukemia (13), chronic myelogenous leukemia(1), malignant lymphoma with bone marrow involvement(1) and multiple myeloma(1). Chemotherpeutic agents evaluated included cytosar, adriamycin, epirubicin, daunorubicin and vincristine. Cyclophosphamide was not studied since the active metabolite, 4-hydroperoxyclophosphamide, was not available. Our results sow that in vitro sensitivity to at least one of the drugs received predicted the response of complete remission in 8 out of 10 patients(80%). Alternatively, in vitro resistance to all drugs received corresponded to lack of complete remission in 6 out of patients(100%). Thus, we concluded that his short term liquid mediumculture method and dye exclusion assay correlated well with in vivo clinical response. This test is simple and rapid and can be applied widely to help in the choice of chemotherapeutic drugs in treating hematologic malignancy. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。